Comparative Pharmacology
Head-to-head clinical analysis: JUNEL 1 20 versus NORLESTRIN 28 1 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL 1 20 versus NORLESTRIN 28 1 50.
JUNEL 1/20 vs NORLESTRIN 28 1/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Ethinyl estradiol is a synthetic estrogen that suppresses gonadotropin release by inhibiting hypothalamic GnRH secretion. Norethindrone acetate is a progestin that suppresses LH surge and thickens cervical mucus to inhibit sperm penetration and alters endometrial development.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days, then repeat.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Ethinyl estradiol: 12-24 hours (terminal half-life). Norethindrone: 5-14 hours (terminal half-life). Achieves steady state within 5-7 days.
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Renal: 30-50% (metabolites as glucuronide and sulfate conjugates). Fecal: 20-40% (biliary elimination of metabolites). Unchanged drug: <5% renal.
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive